NSE · AJOONI
Ajooni Biotech Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹117 Cr with net profit ₹3 Cr — a 2.89% net margin, versus 2.63% the period before.
Shareholding
As of 2026-06-30
- Promoter26.89%
- Public73.11%
60,675 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.75× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Packaged Foods · ranked #1 of 9 by market cap · medians across 5 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Tasty Bite Eatables Ltd. | ₹2,386 Cr | 397.27 | 6.97 | 10.32% | 6.45% |
| Regaal Resources Limited | ₹850 Cr | 50.64 | 1.72 | 11.35% | 4.9% |
| Hexagon Nutrition Limited | ₹763 Cr | 20.21 | 2.66 | 16.26% | 0% |
| Sheetal Cool Products Ltd. | ₹604 Cr | 73.91 | 3.86 | 12.18% | 5.22% |
| Nakoda Group of Industries Ltd. | ₹69 Cr | 91.65 | 2.32 | 5.19% | 3.63% |
| Ajooni Biotech Limited(this company) | — | 79.2 | 0.75 | — | — |
AI analysis
AI-generated · google/gemini-2.5-flashAjooni Biotech Limited is listed on the Indian markets with a market capitalization of Rs 72 Cr. The company reported revenue of Rs 116.76 Cr and a profit margin of 236.3%. Its earnings per share (EPS) stands at Rs 0.25, with a return on equity (ROE) of 473.9%.
Positives
- +The company has a low debt-to-equity ratio of 0.03.
- +Promoter shareholding is not pledged (0%).
- +Net profit has increased to Rs 3.372 Cr in Mar 2025 from Rs 0.3730517 Cr in Mar 2021.
Negatives
- −Promoter holding has decreased to 26.8949% in Mar 2026 from 46.2345% in Jan 2020.
- −The latest annual EPS declined to Rs 0.2 in Mar 2025 from Rs 1.94 in Mar 2023.
- −Return on capital employed (ROCE) is relatively low at 5.9206%.
Financial Performance
Ajooni Biotech Limited's revenue has increased over the past few years, reaching Rs 116.76 Cr in Mar 2025 from Rs 51.056101 Cr in Mar 2021. Net profit also showed growth, rising to Rs 3.372 Cr in Mar 2025 from Rs 0.3730517 Cr in Mar 2021. The latest annual EPS is Rs 0.25 as of Mar 2024, down from Rs 1.94 in Mar 2023. Quarterly revenue in Mar 2026 was Rs 60.62 Cr, with a net profit of Rs 0.95 Cr.
Profitability & Returns
The company's return on equity (ROE) is 473.9% and return on capital employed (ROCE) is 5.9206%. The profit margin is reported at 236.3%. Earnings per share (EPS) for Mar 2024 was Rs 0.25, which represents a decrease from Rs 1.94 in Mar 2023. In the latest full fiscal year (Mar 2025), EPS was Rs 0.2, a decline from the previous year.
Balance Sheet
The debt-to-equity ratio for Ajooni Biotech Limited is 0.03, indicating a very low level of debt relative to equity. The book value per share is Rs 5.29.
Ownership & Pledges
As of Mar 2026, promoter shareholding stands at 26.8949%, while public shareholding is 73.1051%. There are no shares pledged by the promoters. The number of shareholders has significantly increased to 61,779 in Mar 2026 from 360 in Jan 2020.
Data as of — price: 2026-07-30 · financials: Mar 25 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.